Resiquimod
- Generic Name
- Resiquimod
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C17H22N4O2
- CAS Number
- 144875-48-9
- Unique Ingredient Identifier
- V3DMU7PVXF
- Background
A substance being studied in the treatment of some types of skin cancer. When put on the skin, resiquimod causes some immune cells to make certain chemicals that may help them kill tumor cells. It is also being studied to find out if adding it to a tumor vaccine improves the antitumor immune response. It is a type of imidazoquinoline and a type of immunomodu...
- Indication
Investigated for use/treatment in genital herpes.
- Associated Conditions
- -
- Associated Therapies
- -
HighField gains Chinese regulatory clearance to begin solid tumour therapy trial
HighField Biopharmaceuticals received clearance from China’s NMPA to start an open-label Phase I trial of HF50 for advanced solid tumours. The trial, set to begin in Q1 next year, will evaluate HF50’s tolerability, safety, pharmacokinetic characteristics, preliminary efficacy, and immunogenicity. HF50 uses a unique lipid bilayer system, TRAFsome, to harness T-cells to attack cancer cells and includes Resiquimod to boost the anti-tumour immune response.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath